Check the Ownership,they give a number of 28 Institutional Holders, yet the list shows 0, NONE! Check the Insider Transactions, Purchases 175,000 shares, Sales 5.9 Million and that 14 sales and two buys to keep the suckers on the hook. As my grandfather use to tell me " You can lead a horse to water, but you can't make him drink". He also said "A Fool and His Money will soon part Company". Buy ADXS you'll be better off. GLTA
Inovio Pharmaceuticals' Cancer Vaccine Demonstrates for 1st Time that a DNA-Based Therapeutic Vaccine Can Produce Immune Responses to Kill Target Cells
-- Article in Peer-Reviewed Science-Translational Medicine Reports Strong and Durable T Cell Responses from VGX-3100, Which is Designed to Treat Cervical Dysplasias Caused by HPV Infection
-- On-going phase II efficacy study will determine vaccine's ability to reverse disease progression to cervical cancer
Oct 10, 2012
BLUE BELL, Pa., Oct. 10, 2012 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today clinical results indicating that its VGX-3100 therapeutic synthetic vaccine is capable of not only driving robust immune responses to antigens from high risk types of human papillomavirus (HPV) infection but that these immune responses displayed a powerful killing effect on cells changed by HPV into precancerous dysplasias. This desirable effect may ultimately contribute to the regression or elimination of cervical dysplasia and cervical cancer. Inovio is currently assessing the ability of its DNA-based VGX-3100 to treat cervical dysplasias caused by HPV infection in a global phase II trial.
Results from this phase I trial appeared today in the peer-reviewed journal, Science-Translational Medicine, in an article entitled, "Immunotherapy against HPV 16/18 generates potent Th1 and cytotoxic cellular immune responses."
The paper reports that 100% of patients (18 of 18) enrolled in the phase I dose-escalating trial showed antigen-specific antibody responses to Inovio's vaccine, while 78% showed T-cell responses in the validated ELISpot assay. Further tests of T-cell immunity measured the ability of CD8+ T-cells from vaccinated patients to kill cells displaying HPV antigens on their surface: 91% of patients who developed T-cell responses showed the presence of CD8+ T-cells capable of this type of killing activity"